$NBIX

Cooke Julie sold $850K of NBIX

Cooke Julie (Chief Human Resources Officer) sold 5,466 shares of NEUROCRINE BIOSCIENCES INC (NBIX) at $155.46 ($0.85M total) on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cooke Julie
Published Jun 4, 2026, 10:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NBIX
Neutral
high confidence
Mentioned
$NBIX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NBIXNeutralLow
01

Why it matters

The disclosure provides limited incremental information because 10b5-1 plans are designed to reduce timing-based trading signals; impact is mainly sentiment/positioning rather than fundamentals.

02

Market read

Traders may treat as a minor sentiment datapoint; the 10b5-1 qualifier lowers the probability of a strong price reaction.

03

What to watch

The filing does not indicate why the sale occurred or whether future sales/buys are planned; size relative to total holdings is modest (post-transaction 39,631 shares).

Relevance 6/10Novelty 3/10Timing: Filed 2026-06-04 after the 2026-06-02 sale date.

Background

SEC Form 4 discloses insider transactions for Neurocrine Biosciences; this specific sale was conducted via an open-market transaction under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$NBIXNeutralHigh confidence
Context

Neurocrine Biosciences insider (Chief Human Resources Officer) sold $849,725 of NBIX shares under a pre-arranged 10b5-1 plan on 2026-06-02.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted given the stated 10b5-1 pre-arranged plan.

Evidence & confidence

Form 4 reports a routine open-market sale with an explicit pre-arranged 10b5-1 plan, reducing signal strength versus discretionary selling.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None.

None.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with periods of weaker outlook; traders may still watch for follow-on disclosures.

Key entities

  • Neurocrine Biosciences, Inc.

    NBIX insider transaction disclosed on SEC Form 4 (Chief Human Resources Officer sale).

  • Cooke Julie

    Chief Human Resources Officer who sold 5,466 shares at $155.4566 on 2026-06-02 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NBIXMed

Why is Neurocrine Biosciences stock sliding today?

Neurocrine Biosciences (NBIX) shares fell about 3.1% to $156.94 after three Prader-Willi patient groups issued a joint statement citing post-marketing safety data for Neurocrine’s Vykat XR, including seven patient deaths and 100+ serious adverse events reported to the FDA. The groups did not claim causality. CEO Kyle Gano disputed a link. Investors also weighed INGREZZA drug-pricing concerns; Q2 2026 revenue was reported above $950M.

$NBIXMed

Neurocrine Biosciences, Inc. Q2 2026 Earnings Call Summary

Neurocrine Biosciences reported Q2 2026 results and discussed its shift to a diversified portfolio. Management said INGREZZA record new patient additions supported raised full-year guidance midpoint for 13% YoY growth. CRENESSITY launch progress and Soleno and VYKAT XR acquisitions were highlighted. Soleno was $2.9B cash-funded; quarter-end cash was $500M and no debt.

$NBIXMedAI 8/10

Neurocrine (NBIX) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Todd Tushla Chief Executive Officer - Kyle W. Gano Chief Financial Officer - Matthew Abernethy Chief Commercial Officer - Eric S. Benevich Chief Medical Officer - Sanjay Keswani Chief Business Officer - Samir Siddhanti Need a quote from a Motley Fool analyst?

$NBIXHigh

NEUROCRINE BIOSCIENCES INC (NBIX): Results of Operations and Financial Condition

NEUROCRINE BIOSCIENCES INC (NBIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results Total Second-Quarter 2026 Revenue Grew 39% Year-Over-Year to $959 Million INGREZZA ® (valbenazine) 2026 Net Sales Guidance Raised to $2.825 to $2.875 Billion Acquisition of Soleno Therapeutics Compl